Stockreport

New Amsterdam sees success in Phase III cardiovascular disease trial [Yahoo! Finance]

Silence Therapeutics Plc - American Depository Share  (SLN) 
PDF The combination treatment is designed for patients living with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Th [Read more]